Smooth values of polynomials

Given $f\in \mathbb{Z}[t]$ of positive degree, we investigate the existence of auxiliary polynomials $g\in \mathbb{Z}[t]$ for which $f(g(t))$ factors as a product of polynomials of small relative degree. One consequence of this work shows that for any quadratic polynomial $f\in\mathbb{Z}[t]$ and any $\epsilon > 0$, there are infinitely many $n\in\mathbb{N}$ for which the largest prime factor of $f(n)$ is no larger than $n^{\epsilon}$

Additional file 5: Figure. S2. of Timing of delivery in a high-risk obstetric population: a clinical prediction model

Corrected calibration curve of the final model after internal validation. (DOCX 27 kb

Additional file 8: Table S6. of Timing of delivery in a high-risk obstetric population: a clinical prediction model

Sensitivity analysis of the final model restricting to women <32 weeks. (DOCX 14 kb

Additional file 3:Figure S1. of Timing of delivery in a high-risk obstetric population: a clinical prediction model

Kaplan-Meier curve showing the proportion of women who remained pregnant from the time that they were admitted to hospital and identified as being at risk of delivery within 7 days. (DOCX 26 kb

Additional file 1: Table S1. of Timing of delivery in a high-risk obstetric population: a clinical prediction model

A list of all members of the collaborative group in CPN. (DOCX 13 kb

Additional file 7: Table S5. of Timing of delivery in a high-risk obstetric population: a clinical prediction model

Sensitivity analysis of the final model among singleton and multiple pregnancies. (DOCX 13 kb

Monitoring maternal near miss/severe maternal morbidity: A systematic review of global practices

There is international interest in monitoring severe events in the obstetrical population, commonly referred to as maternal near miss or severe maternal morbidity. These events can have significant consequences for individuals in this population and further study can inform practices to reduce both maternal morbidity and mortality. Numerous surveillance systems exist but we lack a standardized approach. Given the current inconsistencies and the importance in monitoring these events, this study aimed to identify and compare commonly used surveillance methods. In June 2018, we systematically searched MEDLINE, EMBASE, and CINAHL using terms related to monitoring/surveillance and maternal near miss/severe maternal morbidity. We included papers that used at least three indicators to monitor for these events and collected data on specific surveillance methods. We calculated the rate of maternal near miss/severe maternal morbidity in hospitalization data obtained from the 2016 US National Inpatient Sample using five common surveillance methods. Of 18,832 abstracts, 178 papers were included in our review. 198 indicators were used in studies included in our review; 71.2% (n = 141) of these were used in 50% of studies included in our review. Eclampsia was the only indicator that was assessed in >80% of included studies. The rate of these events in American hospitalization data varied depending on the criteria used, ranging from 5.07% (95% CI = 5.02, 5.11) with the Centers for Disease Control criteria and 7.85% (95% CI = 7.79, 7.91) using the Canadian Perinatal Surveillance System. Our review highlights inconsistencies in monitoring practices within and between developed and developing countries. Given the wide variation in monitoring approaches observed and the likely contributing factors for these differences, it may be more feasible for clinical and academic efforts to focus on standardizing approaches in developed and developing countries independently at this time

Additional file 1: Figure S1. of MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)—implementation of a national guideline in Canada

Between-centre variability of optimal, under and suboptimal uses of MgSO4 among the 11 participating centres. Figure S2. Trend of antenatal corticosteroid administration over time among women with underuse of MgSO4 as a proxy for non-precipitous deliveries. Figure S3. Variability of MgSO4 use for fetal neuroprotection among MAG-CP centres (represented by the blue triangles) and non-MAG-CP centres (represented by the green circles). Table S1. MAG-CP (MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy), CPN (Canadian Perinatal Network) and CNN (Canadian Neonatal Network) collaborative groups. Table S2. Definitions of conditions and variables as used in the Canadian Perinatal Network (CPN). Table S3. Geographic regions of participating centres in the Canadian Perinatal Network (CPN). Table S4. Absolute utilisation rates of MgSO4 for fetal NP by study time period (from August 01/05 to September 30/15). Table S5. Segmented regression analysis of the nine centres that contributed data to both pre-MAG-CP and MAG-CP eras. Table S6. Sensitivity analyses of overall utilisation rates of MgSO4 using data from the nine centres that contributed data to both pre-MAG-CP and MAG-CP eras. Table S7. Determinants of engagement of participating sites in MAG-CP. Table S8. Components of engagement and relation to optimal use. Table S9. Antenatal MgSO4 use at GA 24–31+6 weeks by indication, from Jan 1/11 to Sep 30/15. (DOCX 281 kb

Additional file 1: Table S1. of Magnesium sulphate for fetal neuroprotection: benefits and challenges of a systematic knowledge translation project in Canada

The MAG-CP (MAGnesium sulphate for prevention of Cerebral Palsy) Collaborative Group. Table S2: Ethical approval numbers by site. Table S3: Barriers and Facilitators Survey. Table S4: Comparison of nodes and sub-nodes between final analysis (by KCT and KC) and re-analysis (by DAD). Panel S2: Final NVivo coding list (nodes and sub-nodes) for analysis. Panel S3: Nature of knowledge identified as needed by respondents (N (%) responses). (DOCX 101 kb

Additional file 2: Panel S1. of Magnesium sulphate for fetal neuroprotection: benefits and challenges of a systematic knowledge translation project in Canada

Discussion forum and course evaluation questions from the e-learning module for MgSO4 for fetal neuroprotection used in data coding and analysis. (DOCX 13.7 KB